Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Isaacs

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of the American Chemical Society|January 15, 2004
Insight into G[bond]T mismatch recognition using molecular dynamics with time-averaged restraints derived from NMR spectroscopyRichard J Isaacs, H Peter Spielmann
DNA Repair|May 28, 2004
A model for initial DNA lesion recognition by NER and MMR based on local conformational flexibilityRichard J Isaacs, H Peter Spielmann
Anti-Cancer Drugs|February 2, 2012
Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cellsNatisha Magan, Richard J Isaacs, Kathryn M Stowell
BMC Molecular Biology|May 22, 2007
Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regionsAmram O Williams, Richard J Isaacs, Kathryn M Stowell
Journal of Molecular Biology|June 8, 2002
Structural differences in the NOE-derived structure of G-T mismatched DNA relative to normal DNA are correlated with differences in (13)C relaxation-based internal dynamicsRichard J Isaacs, William S Rayens, H Peter Spielmann
Expert Opinion on Drug Discovery|September 15, 2009
Cell-based Assays to Identify Inhibitors of Viral DiseaseNeil Green, Robert D Ott, Richard J Isaacs, et al.
Anti-Cancer Drugs|March 14, 2007
Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicinHenning Koehn, Natisha Magan, Richard J Isaacs, et al.
The Biochemical Journal|May 29, 2003
Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factorsNatisha Magan, Agnieszka P Szremska, Richard J Isaacs, et al.
The New Zealand Medical Journal|August 28, 2007
PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decisionRichard J Isaacs, Christopher M Frampton, Marion J J Kuper-Hommel
Anti-Cancer Drugs|April 2, 2004
Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1Kirsty A Allen, Amram O Williams, Richard J Isaacs, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of the American Chemical Society|January 15, 2004
Insight into G[bond]T mismatch recognition using molecular dynamics with time-averaged restraints derived from NMR spectroscopyRichard J Isaacs, H Peter Spielmann
DNA Repair|May 28, 2004
A model for initial DNA lesion recognition by NER and MMR based on local conformational flexibilityRichard J Isaacs, H Peter Spielmann
Anti-Cancer Drugs|February 2, 2012
Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cellsNatisha Magan, Richard J Isaacs, Kathryn M Stowell
BMC Molecular Biology|May 22, 2007
Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regionsAmram O Williams, Richard J Isaacs, Kathryn M Stowell
Journal of Molecular Biology|June 8, 2002
Structural differences in the NOE-derived structure of G-T mismatched DNA relative to normal DNA are correlated with differences in (13)C relaxation-based internal dynamicsRichard J Isaacs, William S Rayens, H Peter Spielmann
Expert Opinion on Drug Discovery|September 15, 2009
Cell-based Assays to Identify Inhibitors of Viral DiseaseNeil Green, Robert D Ott, Richard J Isaacs, et al.
Anti-Cancer Drugs|March 14, 2007
Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicinHenning Koehn, Natisha Magan, Richard J Isaacs, et al.
The Biochemical Journal|May 29, 2003
Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factorsNatisha Magan, Agnieszka P Szremska, Richard J Isaacs, et al.
The New Zealand Medical Journal|August 28, 2007
PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decisionRichard J Isaacs, Christopher M Frampton, Marion J J Kuper-Hommel
Anti-Cancer Drugs|April 2, 2004
Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1Kirsty A Allen, Amram O Williams, Richard J Isaacs, et al.
Pageof 2